Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity
Author: White, D.
Saunders, V.
Dang, P.
Engler, J.
Venables, A.
Zrim, S.
Zannettino, A.
Lynch, K.
Manley, P.
Hughes, T.
Citation: Blood, 2007; 110(12):4064-4072
Publisher: Amer Soc Hematology
Issue Date: 2007
ISSN: 0006-4971
Statement of
Deborah L. White, Verity A. Saunders, Phuong Dang, Jane Engler, Amity Venables, Stephanie Zrim, Andrew Zannettino, Kevin Lynch, Paul W. Manley, and Timothy Hughes
Abstract: Interpatient variability in intracellular uptake and retention (IUR) of imatinib may be due to variable function of the OCT-1 influx pump. OCT-1 activity was measured in pretherapy blood from chronic myeloid leukemia (CML) patients by calculating the difference in IUR of [(14)C]-imatinib with and without OCT-1 inhibition. Of patients with higher than median (high) OCT-1 activity, 85% achieved major molecular response (MMR) by 24 months, versus 45% with no more than a median (low) OCT-1 activity. Assessing patients receiving 600 mg imatinib per day and those averaging fewer than 600 mg over 12 months of therapy revealed patients with high OCT-1 activity achieved excellent molecular response regardless of dose, whereas response of patients with low OCT-1 activity was highly dose dependent. Of patients with low OCT-1 activity who received fewer than 600 mg, 45% failed to achieve a 2-log reduction by 12 months, and 82% failed to achieve a MMR by 18 months, compared with 8% and 17% in the cohort with high OCT-1 activity and dose less than 600 mg/day (P = .017 and P = .022). OCT-1 activity is an important determinant of molecular response to imatinib, with predictive value closely linked to dose. This pretherapy assay identifies patients at greatest risk of suboptimal response where dose intensity is critical, and those likely to respond equally well to standard dose imatinib.
Keywords: Humans
Organic Cation Transporter 1
Protein Kinase Inhibitors
Remission Induction
Risk Factors
Cohort Studies
Dose-Response Relationship, Drug
Drug Resistance, Neoplasm
Time Factors
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib Mesylate
Description: © 2007 by The American Society of Hematology
DOI: 10.1182/blood-2007-06-093617
Published version:
Appears in Collections:Aurora harvest 5
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.